ADGI Stock Recent News
ADGI LATEST HEADLINES
WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious diseases, today announced participation in the following upcoming investor conferences:
Last Friday, health care focused hedge fund M28 Capital filed a 13D/A with the US Securities & Exchange Committee revealing it bought 2.85 million Adagio Therapeutics (US:ADGI) at an average of $4.28 per share, bringing its holding to 9.2 million, or 8.5% of the company.
The stock price of Adagio (ADGI) surge after it reports positive preliminary data from the phase II/III studies, which evaluate its monoclonal antibody for the prevention and treatment of COVID-19.
Penny stocks are a hot subject today with several of the top companies in the market seeing major gains on Wednesday and we know why! The post Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?
Adagio Therapeutics Inc's (NASDAQ: ADGI) Phase 2/3 trials evaluating 300 mg adintrevimab (ADG20) as pre-and-post-exposure prophylaxis (EVADE) and treatment (STAMP) for COVID-19 have met its primary endpoints. Following the emergence of the omicron variant, a pre-specified exploratory.
Investors are reacting to better than expected clinical trial results for its COVID-19 treatment candidate.
Adagio Therapeutics says it will seek an emergency use authorization for its Covid-19 antibody, known as ADG20, in the second quarter.
Here's what you need to know about trading penny stocks on March 30th The post Trading Penny Stocks? Top Stock Market News for March 30th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
There are some investors who buy U.S.-listed stocks that are trading below their liquidation value because they believe there is a lot to gain in these stocks after the market reprices shares to near or above their liquidation value.